Viridian Therapeutics, Inc. Board of Directors

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Dr. Marvin H. Caruthers Ph.D.

Dr. Marvin H. Caruthers Ph.D.

Co-Founder & Scientific Advisory Board Member

Mr. Anthony Casciano

Mr. Anthony Casciano

Chief Commercial Officer

Mr. Seth Harmon

Mr. Seth Harmon

Chief Financial Officer

Dr. Eric N. Olson Ph.D.

Dr. Eric N. Olson Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Mr. Vahe Bedian Ph.D.

Mr. Vahe Bedian Ph.D.

Co-Founder & Scientific Advisor

Ms. Melissa Manno

Ms. Melissa Manno

Chief Human Resources Officer

Dr. Michael R. Bristow M.D., Ph.D.

Dr. Michael R. Bristow M.D., Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.